A letter from the CEO of Aetna sent to the Department of Justice in July warned that the government’s opposition to an attempted merger would cause Aetna to pull out of Obamacare.
The threat went something like: Aetna’s merger with fellow healthcare giant Humana is necessary for its sustainable growth, and its sustainable growth is necessary to participate in the Obamacare state exchanges. In other words: Nice healthcare exchange you got there, would be a shame if something were to happen to it.
The letter, obtained by the Huffington Post through a Freedom of Information Act request, was in response to the DOJ asking if the outcome of the attempted deal would affect Aetna’s participation in Obamacare. The answer was, a lot.
“[I]f the DOJ sues to enjoin the transaction, we will immediately take action to reduce our 2017 exchange footprint,” CEO Mark Bertolini wrote. “[I]nstead of expanding to 20 states next year, we would reduce our presence to no more than 10 states.”
“[I]t is very likely that we would need to leave the public exchange business entirely and plan for additional business efficiencies should our deal ultimately be blocked,” he went on. “By contrast, if the deal proceeds without the diverted time and energy associated with litigation, we would explore how to devote a portion of the additional synergies … to supporting even more public exchange coverage over the next few years.”
Before Bertolini’s letter was published on Wednesday, critics such as Sen. Elizabeth Warren had openly speculated that Aetna’s plan to withdraw from Obamacare was retaliation for the DOJ’s suit against its merger.
“The health of the American people should not be used as bargaining chips to force the government to bend to one giant company’s will,” she wrote in a statement.
Full Content: Huffington Post
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas